Impact of baseline liver function on survival outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with camrelizumab plus rivoceranib vs sorafenib: A post hoc analysis of study CARES-310.

被引：0
|
作者：
Vogel, Arndt
Cheng, Ann-Lii
Shi, Wei
Jang, Seong
Alexander, Laura
Meng, Xianzhang
Raphael, Natalia
Chan, Stephen Lam
机构：
[1] Hannover Med Sch, Dept Gastroenterol Hepatol & Endocrinol, Hannover, Germany
[2] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[3] Jiangsu Hengrui Pharmaceut, Shanghai, Peoples R China
[4] Elevar Therapeut, Ft Lee, NJ USA
[5] Chinese Univ Hong Kong, Hong Kong Canc Inst, Dept Clin Oncol, State Key Lab Translat Oncol, Hong Kong, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
298-3438-2370-5109; 298-3438-9870; 261-566-3248-9542-427-2615-2418; 261-492-11294; 298-3438-10024; 298-3438-2370-7650-2700; 4; 3; 2; 80; 4298; 2950;
D O I：
10.1200/JCO.2024.42.3_suppl.509
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：509 / 509
页数：1
相关论文
共 40 条
  • [1] Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study.
    Vogel, Arndt
    Chan, Stephen Lam
    Ren, Zhenggang
    Bai, Yuxian
    Gu, Shanzhi
    Lin, Xiaoyan
    Chen, Zhendong
    Jia, Weidong
    Jin, Yongdong
    Guo, Yabing
    Hu, Xiaohua
    Sultanbaev, Alexander Valerievich
    Pazgan-Simon, Monika
    Pisetska, Margaryta
    Nip, Tsz Keung
    Zhang, Haisong
    Du, Jinghua
    Cheng, Ann-Lii
    Kaseb, Ahmed Omar
    Qin, Shukui
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Analysis of antidrug antibodies (ADA) to camrelizumab in CARES-310: The pivotal phase III study of camrelizumab plus rivoceranib in unresectable hepatocellular carcinoma (uHCC)
    Kaseb, A. O.
    Bugni, J.
    Karkhanis, M.
    Meng, X.
    Wei, T.
    Zhou, M.
    Shen, K.
    Yang, C.
    Yu, M.
    Jang, S. H.
    Ryan, K.
    Alexander, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S671 - S672
  • [3] Clinical outcomes of camrelizumab plus rivoceranib vs sorafenib (CARES-310) as first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC) of non-viral and viral etiology.
    Shroff, Rachna T.
    Shi, Wei
    Wu, Xiuzhi
    Meng, Xianzhang
    Maj, Melissa
    Ryan, Kristin
    Galloway, Chris
    Alexander, Laura
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL)
  • [4] Patient-reported outcomes (PROs) <65 or ≥ 65 years old (yo) from CARES-310 camrelizumab plus rivoceranib vs sorafenib as first-line treatment for patients with unresectable hepatocellular carcinoma (uHCC)
    Chan, Stephen Lam
    Kaseb, Ahmed Omar
    Shi, Wei
    Alexander, Laura
    Meng, Xianzhang
    Park, Cheolhee
    Ryan, Kristin
    Vogel, Arndt
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 456 - 456
  • [5] Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis to assess the impact of treatment with camrelizumab plus rivoceranib (cam plus rivo) on quality of life vs sorafenib (sora) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study CARES-310
    Moon, A.
    Raphael, N.
    Chan, S. L.
    Kaseb, A. O.
    Jang, S. H.
    Meng, X.
    Cheng, A-L.
    Qin, S.
    Vogel, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S663 - S663
  • [6] Baseline liver function and outcomes in the phase III REFLECT study in patients with unresectable hepatocellular carcinoma (uHCC)
    Vogel, Arndt
    Frenette, Catherine
    Sung, Max W.
    Daniele, Bruno
    Baron, Ari David
    Chan, Stephen Lam
    Blanc, Jean-Frederic
    Tamai, Toshiyuki
    Ren, Min
    Lim, Howard John
    Palmer, Daniel H.
    Takami, Yuko
    Kudo, Masatoshi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [7] Role of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte-ratio (PLR) in unresectable hepatocellular carcinoma (uHCC): Subgroup analysis of patients treated with camrelizumab (cam) plus rivoceranib (rivo) in the CARES-310 trial
    Burgoyne, Adam
    Kaseb, Ahmed Omar
    Shi, Wei
    Alexander, Laura
    Meng, Xianzhang
    Ryan, Kristin
    Galloway, Chris
    Neubach, Will
    Vogel, Arndt
    Chan, Stephen Lam
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [8] Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
    Qin, Shukui
    Chan, Stephen L.
    Gu, Shanzhi
    Bai, Yuxian
    Ren, Zhenggang
    Lin, Xiaoyan
    Chen, Zhendong
    Jia, Weidong
    Jin, Yongdong
    Guo, Yabing
    Hu, Xiaohua
    Meng, Zhiqiang
    Liang, Jun
    Cheng, Ying
    Xiong, Jianping
    Ren, Hong
    Yang, Fang
    Li, Wei
    Chen, Yajin
    Zeng, Yong
    Sultanbaev, Alexander
    Pazgan-Simon, Monika
    Pisetska, Margaryta
    Melisi, Davide
    Ponomarenko, Dmitriy
    Osypchuk, Yurii
    Sinielnikov, Ivan
    Yang, Tsai-Sheng
    Liang, Xiao
    Chen, Chunxia
    Wang, Linna
    Cheng, Ann-Lii
    Kaseb, Ahmed
    Vogel, Arndt
    LANCET, 2023, 402 (10408): : 1133 - 1146
  • [9] Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial
    Qin, S.
    Chan, L. S.
    Gu, S.
    Bai, Y.
    Ren, Z.
    Lin, X.
    Chen, Z.
    Jia, W.
    Jin, Y.
    Guo, Y.
    Sultanbaev, A. V.
    Pazgan-Simon, M.
    Pisetska, M.
    Liang, X.
    Chen, C.
    Nie, Z.
    Wang, L.
    Cheng, A-L.
    Kaseb, A.
    Vogel, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1401 - S1402
  • [10] Post hoc analysis in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function in the phase 3 REFLECT study of lenvatinib vs sorafenib
    Huynh, J.
    Cho, M.
    Kim, E.
    Ren, M.
    Amaya-Chanaga, C.
    Vogel, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S123 - S124
1234